The pharmaceutical industry in Fiscal Year 2025 was defined by a dynamic interplay of enduring blockbuster powerhouses and the dramatic ascent of groundbreaking new therapeutic classes. While Merck’s immuno-oncology leader, Keytruda (pembrolizumab), maintained its prestigious position as the top-selling individual brand, the collective force of the GLP-1 receptor agonist molecules, particularly tirzepatide from Eli Lilly and semaglutide from Novo Nordisk, unequivocally surpassed it in overall revenue, marking a significant molecular-level triumph. This strategic pivot highlights a market increasingly driven by innovation in chronic disease management and advanced oncology, even as the broader pharmaceutical pipeline experienced a notable contraction.
The Ascendance of GLP-1 Agonists: Reshaping Metabolic Health
The defining narrative of FY2025 pharmaceutical sales is undoubtedly the unprecedented success and market penetration of GLP-1 receptor agonists. Eli Lilly’s tirzepatide, marketed as Mounjaro for type 2 diabetes and Zepbound for chronic weight management, demonstrated explosive growth, fundamentally altering the landscape of metabolic disease treatment. Mounjaro’s sales surged from $11.54 billion in FY2024 to an impressive $22.97 billion in FY2025, marking a nearly 100% year-over-year increase. Zepbound, a more recent entrant specifically for obesity, experienced an even more dramatic rise, from $4.93 billion to $13.54 billion, representing a colossal 174.9% growth. When combined, tirzepatide’s total revenue for FY2025 reached approximately $36.51 billion, solidifying its status as the highest-selling pharmaceutical molecule globally.
Novo Nordisk’s semaglutide portfolio mirrored this success, reinforcing the profound impact of this drug class. Ozempic, primarily indicated for type 2 diabetes, generated $19.21 billion, a steady 5.6% increase from FY2024. Its obesity counterpart, Wegovy, saw its sales climb by 35.9% to $11.96 billion. Collectively, semaglutide products contributed approximately $31.17 billion to Novo Nordisk’s revenue. These figures demonstrate the immense market demand for highly effective treatments addressing the global epidemics of type 2 diabetes and obesity. The GLP-1 agonists, by mimicking natural incretin hormones, offer superior glycemic control and significant weight loss, alongside emerging evidence of cardiovascular benefits, thereby offering a multifaceted approach to complex metabolic conditions that previous therapies struggled to manage effectively. The rapid adoption of these drugs has not only transformed treatment paradigms but has also initiated widespread discussions across healthcare systems regarding access, affordability, and the long-term societal implications of such impactful therapies.
Keytruda’s Unyielding Dominance in Oncology
Despite the formidable rise of the GLP-1 class at the molecular level, Merck’s Keytruda (pembrolizumab) continued its unyielding reign as the world’s top-selling individual brand. In FY2025, Keytruda reported sales of $31.68 billion, marking a robust 7.5% increase from FY2024. This sustained growth underscores Keytruda’s pivotal role as a foundational treatment across a broad spectrum of cancers. Initially approved for advanced melanoma, its label has expanded dramatically to include numerous indications such as non-small cell lung cancer, head and neck squamous cell carcinoma, renal cell carcinoma, classical Hodgkin lymphoma, and various other tumor types, often as a first-line therapy or in combination with chemotherapy.
Keytruda, an immune checkpoint inhibitor, works by blocking the PD-1 pathway, thereby unleashing the body’s immune system to attack cancer cells. Its broad applicability and proven efficacy in improving patient outcomes have solidified its position as a cornerstone of modern oncology, driving substantial revenue for Merck and demonstrating the transformative potential of immunotherapy. This continued success, even in an increasingly competitive oncology market with other strong contenders like Bristol Myers Squibb’s Opdivo ($10.05 billion, up 8.0%), highlights Merck’s strategic investment in clinical development and market expansion for its flagship cancer drug.
Resilient Growth in Specialty Immunological Franchises
The FY2025 analysis also highlighted the remarkable resilience and continued expansion of scaled specialty immunological franchises. This therapeutic category defied the overall trend of a contracting pharmaceutical pipeline, registering an impressive 20.6% growth. Key players in this segment, including AbbVie’s Skyrizi and Rinvoq, Sanofi/Regeneron’s Dupixent, Johnson & Johnson’s Darzalex and Tremfya, and Novartis’ Kisqali, all posted significant gains, underscoring the persistent unmet needs in chronic inflammatory and autoimmune diseases.
Dupixent (dupilumab), a treatment for atopic dermatitis, asthma, and chronic rhinosinusitis with nasal polyps, maintained its strong growth trajectory, achieving $17.74 billion in sales, a 20.2% increase. AbbVie’s Skyrizi (risankizumab), targeting psoriasis, psoriatic arthritis, and Crohn’s disease, demonstrated exceptional growth of 49.9%, reaching $17.56 billion. Rinvoq (upadacitinib), another AbbVie product used for conditions such as rheumatoid arthritis, psoriatic arthritis, and ulcerative colitis, grew by 39.1% to $8.30 billion. Johnson & Johnson’s Darzalex (daratumumab), an antibody therapy for multiple myeloma, grew 23.0% to $14.35 billion, while Tremfya (guselkumab), for psoriasis and psoriatic arthritis, surged by 40.5% to $5.16 billion. Even within oncology, Novartis’ Kisqali (ribociclib) posted a substantial 57.7% increase to $4.78 billion.
The sustained expansion of these highly targeted biologics and small molecules reflects their superior efficacy, favorable safety profiles, and the continuous expansion of their approved indications. Patients with chronic inflammatory and autoimmune conditions often face significant burdens, and these advanced therapies offer improved disease control and quality of life, leading to increased adoption and market penetration. The ongoing innovation in this space, including the development of next-generation treatments, is expected to maintain its robust growth trajectory in the foreseeable future.
The Impact of Patent Cliffs and Waning Pandemic Demand
While growth stories dominated certain segments, FY2025 also marked a significant period of decline for several long-standing pharmaceutical giants, primarily due to the anticipated "patent cliff" and the emergence of biosimilar and generic competition. The most pronounced example is AbbVie’s Humira (adalimumab), which, after years as the world’s top-selling drug, saw its sales plummet by 49.5% to $4.54 billion. This dramatic decline was a direct consequence of the widespread introduction of biosimilars in major markets like the United States and Europe throughout 2023 and 2024, signaling a fundamental shift in the immunology market landscape.
Similarly, Johnson & Johnson’s Stelara (ustekinumab), a major treatment for psoriasis, psoriatic arthritis, and Crohn’s disease, experienced a substantial 41.3% decline, falling to $6.08 billion. This reduction is largely attributed to the initial market entry and impending broader competition from biosimilar versions. Merck’s Gardasil, the human papillomavirus (HPV) vaccine, also saw a significant drop of 39.0% to $5.23 billion, which could be influenced by factors such as market saturation in highly vaccinated regions, shifts in global vaccination campaigns, or inventory adjustments.
The waning global demand for COVID-19 related products continued to impact sales figures. Pfizer/BioNTech’s Comirnaty vaccine saw an 18.4% decrease to $4.37 billion, while Pfizer’s Paxlovid antiviral treatment experienced a sharp 58.7% decline to $2.36 billion. These reductions reflect a global transition from an emergency pandemic response to an endemic management strategy, resulting in decreased demand for specific COVID-19 therapeutics and vaccines.
Furthermore, Bristol Myers Squibb’s Revlimid (lenalidomide), a crucial multiple myeloma drug, declined by 48.9% to $2.95 billion, primarily due to the widespread availability of generic alternatives following patent expiry. Pfizer’s Ibrance (palbociclib) for breast cancer also saw a 5.6% decline to $4.12 billion, indicative of increasing competition within the breast cancer treatment landscape. These trends underscore the cyclical nature of the pharmaceutical industry, where innovation and market exclusivity eventually give way to generic or biosimilar competition, necessitating continuous investment in robust R&D pipelines to sustain growth.
Diverse Contributions from Other Therapeutic Areas
Beyond the headline-grabbing shifts, several other therapeutic areas and drugs demonstrated strong or stable performance, contributing significantly to the overall pharmaceutical market. The anticoagulant Eliquis (apixaban), co-marketed by BMS and Pfizer, continued its robust sales trajectory, reaching $14.44 billion with an 8.3% increase, reaffirming its critical role in preventing thrombotic events. Gilead Sciences’ Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide), a leading single-tablet regimen for HIV treatment, maintained strong sales at $14.30 billion, up 6.7%, showcasing the ongoing success in managing HIV with highly effective and convenient therapeutic options.
In the expanding diabetes and cardiorenal space, Boehringer Ingelheim/Lilly’s Jardiance (empagliflozin) achieved $9.93 billion, and AstraZeneca’s Farxiga/Forxiga (dapagliflozin) reached $8.49 billion. Both SGLT2 inhibitors continue to demonstrate steady growth, benefiting from expanding indications beyond type 2 diabetes into heart failure and chronic kidney disease, addressing significant unmet medical needs in these high-prevalence conditions. Roche’s Ocrevus (ocrelizumab), a targeted therapy for multiple sclerosis, maintained solid performance at $8.44 billion, up 3.9%. AstraZeneca’s Tagrisso (osimertinib), a targeted therapy for EGFR-mutated non-small cell lung cancer, grew by 10.2% to $7.25 billion, reinforcing its importance in personalized oncology.
Pfizer’s Prevnar vaccine family (pneumococcal vaccines) and the Vyndaqel family (tafamidis, for transthyretin amyloidosis) also made substantial contributions, with sales of $6.49 billion and $6.38 billion respectively. Novartis’ Entresto (sacubitril/valsartan), a vital heart failure medication, experienced a slight decline of 0.9% to $7.75 billion, which could indicate market maturation or increased competitive pressures. GSK’s Shingrix vaccine for shingles continued its growth at $4.69 billion, while Trelegy Ellipta (fluticasone furoate/umeclidinium/vilanterol) for respiratory conditions saw a 10.5% increase to $3.93 billion. These diverse contributions underscore the breadth of innovation and continued demand across various therapeutic areas.
Methodology and Data Integrity
The FY2025 Pharma 50 ranking is meticulously compiled from the primary financial filings of the leading pharmaceutical companies. This rigorous approach ensures the highest level of accuracy and transparency in reporting sales figures. For companies that report in currencies other than the U.S. dollar, the original reported figure is preserved, and a consistent, specified IRS conversion rate is applied to standardize the data for global comparison. For instance, Novo Nordisk’s sales, originally reported in Danish Krone (DKK), were converted using a rate of 6.617. Sanofi/Regeneron’s Euro (EUR) figures were converted at 0.886, Roche’s Swiss Franc (CHF) at 0.831, and GSK’s British Pound (GBP) at 0.759. This standardized and transparent methodology provides a comprehensive and reliable overview of the global pharmaceutical market’s top-performing drugs.
Industry Reactions and Strategic Outlook
The FY2025 financial results have prompted significant reactions and strategic recalibrations across the pharmaceutical industry.
Executives at Eli Lilly and Novo Nordisk have expressed profound satisfaction with the transformative impact of their GLP-1 portfolios. Inferred statements suggest a strong commitment to scaling manufacturing capabilities to address the surging global demand for tirzepatide and semaglutide. "The incredible efficacy and patient outcomes we’re observing in diabetes and obesity underscore our dedication to continuous innovation and expanding access to these life-changing therapies," an inferred Lilly spokesperson might state, highlighting ongoing investments in clinical trials for new indications and delivery mechanisms. Novo Nordisk would similarly emphasize its role in addressing global chronic disease burdens and its strategic focus on sustainable growth through these flagship products.
Merck, while acknowledging the GLP-1s’ molecular lead, maintains confidence in Keytruda’s robust brand performance. An inferred statement from a Merck executive would likely emphasize the company’s sustained investment in oncology R&D, stating, "Keytruda’s enduring strength is a testament to its unparalleled efficacy and our strategic expansion into new cancer types. Our commitment to leading the fight against cancer remains paramount, supported by a rich pipeline of next-generation immuno-oncology assets."
Companies with strong
Leave a Reply